Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

SAN DIEGO, Oct. 23 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology, today reported its financial results and highlights for the third quarter ended September 30, 2008.

"We continue to make rapid progress in both of our hepatitis C development programs," said Steve Worland Ph.D., President and CEO of Anadys. "We completed our first clinical study of ANA598 in healthy volunteers and have now completed the healthy volunteer portion of our ongoing ANA773 study. For both programs, we are very encouraged by the data and look forward to initiating patient dosing this quarter."

Financial Results

As of September 30, 2008, the Company's cash, cash equivalents and securities available-for-sale totaled $34.4 million.

During the third quarter of 2008 the Company had no revenue, compared to $21.5 million for the same quarter of 2007. The revenue in the third quarter of 2007 was primarily derived from the recognition of previously deferred revenue associated with an upfront payment and a milestone payment under a prior collaboration.

Research and development expenses were $7.6 million for the third quarter of 2008 and 2007. During the third quarter of 2008, cost savings derived from Anadys' completed strategic restructuring and associated termination of prior development programs were offset by a significant increase in ANA598 development costs.

General and administrative expenses were $2.1 million for the third quarter of 2008, compared to $2.4 million for the third quarter of 2007. The $0.3 million decrease primarily resulted from cost savi
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... , June 2, 2015 /PRNewswire/ - Aptose Biosciences Inc. ... developing new therapeutics that target the underlying mechanisms of ... Administration (FDA) has granted the company orphan drug designation ... (AML). APTO-253, a first-in-class inducer of the KLF4 gene, ... Ib clinical trial in patients with AML, high-risk myelodysplastic ...
(Date:6/2/2015)... NEW YORK , Jun. 02, 2015 /PRNewswire/ ... "Company"), a diversified life sciences company with interests ... a proprietary synthetic biology platform technology, today announced ... to Typenex Co-Investment, LLC ("Typenex") in exchange for ... January 16, 2015, the Company and Typenex entered ...
(Date:6/2/2015)... Meet ARGUS, The World,s First ... Read People. Analyze emotions and predict actions. Explore a ... very first Responsive-RPG: "The Eye: Genesis".      ... , , https://www.youtube.com/watch?v=B1ZEtAZ2Yf8 ... inner feelings - and those of others. Being able ...
(Date:6/2/2015)... , June 2, 2015   Hospira, Inc. ... biosimilars, today announced that its partner, Celltrion – a global ... the National Health Surveillance Agency in Brazil ... monoclonal antibody approved for use in Brazil ... Hospira also markets and sells biosimilar infliximab in 26 ...
Breaking Biology Technology:Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 2Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 3Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 4Tauriga Sciences, Inc. Extinguishes All Further Obligations to Typenex Co-Investment LLC with One-Time Cash Payment of $230,000 USD 2Tauriga Sciences, Inc. Extinguishes All Further Obligations to Typenex Co-Investment LLC with One-Time Cash Payment of $230,000 USD 3Tauriga Sciences, Inc. Extinguishes All Further Obligations to Typenex Co-Investment LLC with One-Time Cash Payment of $230,000 USD 4ARGUS - The World's First Inner Emotion Scanner Launches on KickStarter 2ARGUS - The World's First Inner Emotion Scanner Launches on KickStarter 3ANVISA Approves First Infliximab Biosimilar in Brazil 2ANVISA Approves First Infliximab Biosimilar in Brazil 3ANVISA Approves First Infliximab Biosimilar in Brazil 4ANVISA Approves First Infliximab Biosimilar in Brazil 5
... Technology (QUT) researchers have developed new technology capable ... aiding clean-up efforts following nuclear disasters. The ... to clean up millions of tonnes of water ... the concentrated waste. Professor Huai-Yong Zhu from ...
... Cadence Pharmaceuticals, Inc. (NASDAQ: CADX ), a ... products principally for use in the hospital setting, today ... will present the company,s corporate overview on Wednesday, November ... during the Credit Suisse Healthcare Conference at the Arizona ...
... Axia Value Chain, a market leader in business ... of their Life Sciences and Health Care Practice Group. ... with global clients in the Health Care and Life ... services, practice development, and service offerings concentrating on alignment ...
Cached Biology Technology:Technology makes storing radioactive waste safer 2Axia Value Chain Appoints John Christina Managing Director of Life Sciences Practice 2
(Date:5/7/2015)... 7, 2015 Fingerprint Cards ... and FPC1035, FPC,s smallest touch fingerprint sensors to ... considered for integration on the backside of the ... increased possibilities to integrate touch fingerprint sensors in ... improves possibilities for module manufacturers to customize the ...
(Date:4/27/2015)... OXFORD, Conn. , Apr. 27, 2015 ... "Company"), a biometric authentication company focused on the growing ... will commence shipping to pre-order customers the first week ... pre-orders through the month of May. ... is a significant milestone for the company as Wocket® ...
(Date:4/20/2015)... 20, 2015 The announcement comes ... Glenbeigh Records Management (GRM), Ireland,s foremost ... Bank. Having built up an impressive track record of clients ... player within the records management sector in Dubai ... is GCC staffbase and employ a further eight staff members ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
... RENO, Nev. Butterfly populations in California are declining and, ... Nevada due to climate change and loss of habitat, according ... of Nevada, Reno assistant professor in the College of Science. ... source for small mammals and birds," Forister said. "They play ...
... Would you pay more for certain products to ... carbon-offset industry proponents pay more money for carbon-producing ... carbon emissions will be balanced out by funding for ... climate scientists agree that a carbon tax would be ...
... are stunted, verging on the edge of survival. It ... conditions. A study published last week in Forest ... their genetic characteristics trees are unable to properly benefit ... surprised to find that the mortality of established trees ...
Cached Biology News:Climate change and habitat destruction affect butterfly populations 2You say offset, I say tax? Study suggests labels and political affiliation may affect preferences 2Northern forests do not benefit from lengthening growing season 2
... derived from frozen embedded tissue blocks, which ... to ensure the highest quality. Tissues of ... block, sectioned at a thickness of 7 ... are large (3-5 mm in diameter) in ...
... tissue microarrays are derived from Paraffin embedded ... quality control procedures to ensure the highest ... assembled in one block, sectioned at a ... coated slides. Sections are large (3-5 mm ...
... from Paraffin embedded tissue blocks, which are ... ensure the highest quality. Tissues of each ... sectioned at a thickness of 5 microns ... large (3-5mm in diameter) in comparison to ...
... Engine Opticon real-time PCR detection system uses ... excitation (450-495 nm) and a photomultiplier tube ... system is built on an DNA Engine ... gradient feature. This item includes the thermal ...
Biology Products: